Stocktoria
Polaryx Therapeutics, Inc. PLYX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2026-02-02
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$7.8M | -$4.4M |
| Net income | -$9.0M | -$30.4M |
| Operating cash flow | -$3.9M | -$2.6M |
| Total assets | $5.2M | $5.0M |
| Total liabilities | $605,000 | $289,000 |
| Shareholders' equity | $4.6M | $4.7M |
| Ratios | ||
| Return on assets | -173.8% | -607.0% |
| Return on equity | -196.8% | -644.2% |
| Current ratio | 8.55 | 17.30 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002075320 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.